重要性是模型對已發布報導給出的 1–5 分，不是對市場的預測。
已排定事件列上的影響是公司顯著度層級（高/中由圖譜中心度與規模判定；低僅用於人工整理的次要事件），不是對波動幅度的預測。
標記為已確認的財報日期，是 Yahoo Finance 認定由公司確認的；預估表示尚未公布。未加標記的列沒有可查的出處記錄。
經濟數據發布屬於總體經濟、不歸屬任何產業，因此在任何檢視下都會保留。沒有數值的發布表示尚未公布，頁面會直說，而不是顯示為零。
涵蓋被追蹤公司的即將到來的事件；已過去的事件會歸檔，並在可得時補上結果——這些結果都經人工整理並附引用，絕不杜撰。沒有結果的歷史列會顯示「結果待定」。
閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數，或指數基金必須買進的股數，以佔流通股的比例表示——依招股說明書或指數編製方法讀出，兩個數字都在該列註明出處。它陳述的是機制，不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估，直到公司自己說明為止。
10月13日週二 · 今天
10月14日週三
7月30日週四
財報
Eversource Energy reported second-quarter 2026 "GAAP earnings of $53.7 million, or $0.14 per share," and "Non-GAAP recurring earnings totaled $329.1 million, or $0.87 per share." The company reaffirmed "2026 non-GAAP recurring earnings of between $4.57 per share and $4.72 per share" and a "cumulative long-term earnings per share growth rate within the range of 5 to 7 percent through 2030."
大盤 開啟原文 ↗
財報
First Solar reported Q2 2026 net sales of $1.06 billion, "a decrease of 4% year-over-year," and net income of $423 million, or $3.92 per diluted share, versus $342 million or $3.18 per diluted share a year earlier. Adjusted EBITDA was $644 million. The company reaffirmed its 2026 guidance and reported a "Contracted sales backlog of 45.1 GW as of June 30, 2026," noting it "surpassed 100 GW of cumulative module sales globally."
大盤 開啟原文 ↗
財報
Sanofi announced the availability of its half-year financial report for the period ended June 30, 2026, filed with French and US regulators. The release points to Q2 results reporting "Q2 sales growth of 17.8% at CER" and "business earnings per share (EPS) of EUR 2.09," with "2026 guidance upgraded."
大盤 開啟原文 ↗
財報
Madrigal Pharmaceuticals reported "Second-quarter 2026 Rezdiffra (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71%." Management noted Rezdiffra "has already achieved nearly $1.3 billion in trailing-12-month net sales."
大盤 開啟原文 ↗
產品
Pfizer reported positive topline results from the Phase 3 TRANQUILLO and TRANQUILLO 2 studies of LITFULO (ritlecitinib) in nonsegmental vitiligo. Per the release, "Across both studies, significantly more patients treated with LITFULO achieved F-VASI75 (>=75% improvement in Facial Vitiligo Area Scoring Index) and T-VASI50 (>=50% improvement in Total Vitiligo Area Scoring Index) from baseline at Week 52 compared with placebo." Pfizer states it "intends to submit global regulatory filings for LITFULO as a potential new oral systemic therapy for NSV for adults."
